Serono to pay over $700 million to settle federal charges

Share this article:
Swiss drug maker Serono will pay more than $700 million to settle federal charges that it illegally marketed its AIDS drug Serostim by developing a fraudulent medical test to increase demand for the drug and sent doctors on all-expenses paid vacations to France in exchange for writing prescriptions.
The settlement marks the third largest healthcare fraud recovery in the history of the U.S. Justice Department and is the largest settlement involving losses to the federal- and state-funded Medicaid program.
"This settlement concludes a four-year government investigation into commercial practices related to Serostim, and we are pleased to put the matter behind us," said Thomas Gunning, vice president and general counsel, Serono U.S., in a statement. "The activities described in the settlement were confined to one unit in our U.S. operations and cover a brief period in our history. Serono takes compliance issues very seriously and has a rigorous compliance program to ensure that its employees meet the highest ethical standards. We now look forward to continuing to focus and devote our energies on our core mission of developing treatments to meet unmet medical needs."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.